Basilea Pharmaceutica AG: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Wright Reports
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Basilea Pharmaceutica AG's oncology drug candidate BAL101553 shows first evidence of antitumor activity in phase 1 study
Basilea Pharmaceutica AG:Says that phase 1 study results of its investigational oncology drug, BAL101553, were presented at American Society of Clinical Oncology (ASCO) annual meeting in Chicago, U.S.A.Maximum tolerated dose (MTD) was determined and results indicated first evidence of clinical antitumor activity.BAL101553 is an intravenous and oral microtubule-targeting agent (MTA.Previous preclinical studies demonstrated that investigational drug has potent anti-cancer activity in tumor models refractory to conventional MTAs.It was shown to arrest tumor cell proliferation and to induce tumor cell death through a destabilizing effect on microtubules which are an intracellular network essential for cell division. In addition, tumor-specific vascular disruption activity was observed in preclinical cancer models.Currently reported phase 1 open-label, dose-escalation study included adult patients with advanced solid tumors who had failed standard therapy.Study investigated safety and tolerability of intravenous BAL101553 and evaluated pharmacokinetics, pharmacodynamics and antitumor activity.
Latest Developments for Basilea Pharmaceutica AG
- Basilea Pharmaceutica AG says Swissmedic approves Zevtera
- Basilea Pharmaceutica AG reports granting of U.S. orphan drug designation to isavuconazole for treatment of invasive candidiasis
- Basilea Pharmaceutica AG receives notification from U.S. FDA of acceptance of filing of isavuconazole NDA for the treatment of invasive aspergillosis and invasive mucormycosis
- Basilea Pharmaceutica AG confirms FY 2014 guidance
- Share this
- Digg this